Details for Patent: 11,179,367
✉ Email this page to a colleague
Which drugs does patent 11,179,367 protect, and when does it expire?
Patent 11,179,367 protects TRIKAFTA (COPACKAGED) and is included in two NDAs.
This patent has fifteen patent family members in thirteen countries.
Summary for Patent: 11,179,367
Title: | Pharmaceutical compositions for treating cystic fibrosis |
Abstract: | A pharmaceutical composition comprising Compound I: ##STR00001## Methods of treating cystic fibrosis comprising administering one or more of such pharmaceutical compositions to a patient. |
Inventor(s): | Chu; Cathy (Cambridge, MA), Dhamankar; Varsha (Watertown, MA), Dokou; Eleni (Cambridge, MA), Haseltine; Eric L. (Melrose, MA), Moskowitz; Samuel (Waban, MA), Robertson; Sarah (Somerville, MA), Waltz; David (Waban, MA), Chen; Weichao George (San Diego, CA) |
Assignee: | Vertex Pharmaceuticals Incorporated (Boston, MA) |
Application Number: | 16/267,222 |
Patent Claim Types: see list of patent claims | Use; Composition; Compound; Dosage form; |
Drugs Protected by US Patent 11,179,367
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | GRANULES;ORAL | 217660-001 | Apr 26, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO | ⤷ Try a Trial | |||
Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | GRANULES;ORAL | 217660-002 | Apr 26, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO | ⤷ Try a Trial | |||
Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | TABLET;ORAL | 212273-002 | Jun 8, 2021 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO AT LEAST ONE OF CLAIMS 1-9 OF US11179367 | ⤷ Try a Trial | |||
Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | TABLET;ORAL | 212273-001 | Oct 21, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO AT LEAST ONE OF CLAIMS 1-9 OF US11179367 | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,179,367
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 114581 | ⤷ Try a Trial | |||
Australia | 2019215231 | ⤷ Try a Trial | |||
Brazil | 112020014487 | ⤷ Try a Trial | |||
Canada | 3088272 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |